1Meta-Analysis2024
Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I, Dos Santos HV · Arch Endocrinol Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
45 peer-reviewed studies
What the evidence says
Most Orforglipron studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2023–2026 with a typical study size of 546 participants.
Based on 45 studies · 11 meta-analyses · 18 RCTs · 12,476 total participants
Confidence
High confidenceBy outcome
45 studies in the last 5 years · Latest meta-analysis: 2026
Lütkemeyer C, Pasqualotto E, Ferreira ROM, Chavez MP, Petris I, Dos Santos HV · Arch Endocrinol Metab (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A · Metabolism (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hageen AW, Gadelmawla AF, Saleh AO, Mohamed MR, Abdallfatah A, Elsekhary A · Endocrinol Diabetes Metab (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H · BMJ (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Hammad N, Ramadan AM, Nazmy A, Elazab A, Abdelaziz A · Diabetes Technol Ther (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 with the 12-mg dose, -1.48 with the 36-mg dose, and -0.41 with placebo.
Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, Liu R, Li J, Fernández Landó L, Denning M, Ludwig L, Chen Y; ACHIEVE-1 Trial Investigators. · N Engl J Med (2025)
Hegaz MG, Aboud MYA, Kamel AII, Naveed MA, Elsayed OG, Sorathia AZ · BMC Endocr Disord (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Li H, Yu G, Huang Q, Yang B, Nie J, Liu Y · Biomed Pharmacother (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: While gastrointestinal tolerability remains a clinically important limitation requiring mitigation strategies, orforglipron represents a promising oral therapeutic option for comprehensive obesity and metabolic management.
Pandey RK, Jan M, Mohammad A, Jawaid KA, Naveed M, Abid MA, Amir AB, Ahmed S, Safiullah M, Bhatti MI, Iftikhar S, Saddique MN, Alfalh W, Omar RMB, Abu Dawood H. · Endocrinology, diabetes & metabolism (2025)
In plain English: Change from baseline in mean HbA1c was -1.23%, -1.50%, and -1.56% with orforglipron 3 mg, 12 mg, and 36 mg, respectively, versus -0.81% with dapagliflozin 10 mg.
Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y; ACHIEVE-2 Trial Investigators. · Lancet (2026)
Takrori E, Peshin S, Singal S · Medicina (Kaunas) (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Alsaqaaby MS, Cooney S, le Roux CW, Pournaras DJ · Lancet Diabetes Endocrinol (2024)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Luna Ceron E, Reddy SD, Kattamuri L, Muvva DM, Chozet L, Bright T · J Brown Hosp Med (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
In plain English: TSA indicates conclusions for weight, BMI, and SBP are robust; longer-term comparative trials should refine DBP and safety signals.
Jamal A, Khan S, Qadri M, Shah A, Iftikhar H, Fatima E, Ahmad M, Sikandar M, Jawed I, Muneeb M, Mohmand MS, Bacha Z, Khan BW, Jamal T, Khalid AA, Khan MI, Zulkaif M. · Acta diabetologica (2026)
In plain English: At week 40, the mean changes from baseline in HbA1c were -1.58%, -1.88%, and -1.82% with orforglipron 3 mg, 12 mg, and 36 mg once daily, respectively, vs -0.79% with placebo.
Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J. · JAMA (2026)
Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M · Lancet (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K · N Engl J Med (2025)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Horn DB, Ryan DH, Kis SG, Alves B, Mu Y, Kim SG · Lancet (2026)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R · N Engl J Med (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.
Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW · Diabetes Obes Metab (2023)
No plain-language summary recorded for this citation — open the paper to read its abstract.